Oxindole

Oxindole

SCHEMBL2299434

C1=CCCC2CCNC2=C1.O=C1Cc2ccccc2N1

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 4/20 0.51
PDK2 Q15119 1/20 0.51
NPC1 O15118 2/20 0.37
MAPK13 O15264 1/20 0.37
MAPK12 P53778 1/20 0.37
MAPK11 Q15759 1/20 0.37
MAPK14 Q16539 1/20 0.37
BRD4 O60885 1/20 0.36
CREBBP Q92793 1/20 0.36
EPHX2 P34913 1/20 0.36
MAPT P10636 2/20 0.35
SRC P12931 1/20 0.35
SMYD3 Q9H7B4 3/20 0.33
TDP2 O95551 1/20 0.33
CASP3 P42574 1/20 0.33
CASP7 P55210 1/20 0.33
CASP9 P55211 1/20 0.33
CASP6 P55212 1/20 0.33
CASP8 Q14790 1/20 0.33
MAP3K14 Q99558 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxindole SCHEMBL19504 0.72 AHR (1.00) AHRPDK2NPC1MAPK13MAPK12
Oxindole SCHEMBL29358826 0.72 AHR (1.00) AHRPDK2NPC1MAPK13MAPK12
Oxindole SCHEMBL1144643 0.72 AHR (1.00) AHRPDK2NPC1MAPK13MAPK12
Oxindole SCHEMBL1236964 0.70 AHR (0.95) AHRPDK2NPC1MAPK13MAPK12
Oxindole SCHEMBL4720301 0.70 AHR (0.95) AHRPDK2NPC1MAPK13MAPK12
Oxindole SCHEMBL1462135 0.70 AHR (0.95) AHRPDK2NPC1MAPK13MAPK12
Oxindole SCHEMBL8866524 0.70 AHR (0.95) AHRPDK2NPC1MAPK13MAPK12
Oxindole SCHEMBL15636313 0.70 AHR (0.95) AHRPDK2NPC1MAPK13MAPK12
Oxindole SCHEMBL5502064 0.70 AHR (0.95) AHRPDK2NPC1MAPK13MAPK12
Oxindole SCHEMBL5668060 0.70 AHR (0.95) AHRPDK2NPC1MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7998688-B2 Inhibition of EMT induction in tumor cells by anti-cancer agents OSI Pharmaceuticals, LLC (US) 2011-08-16 US disclosed
US-20090286850-A1 Inhibition of EMT induction in tumor cells by anti-cancer agents SHAABAN SALAM A 2009-11-19 US disclosed
US-20040186160-A1 Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors SUGEN, INC. 2004-09-23 US disclosed
US-20040186160-A1 Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors SUGEN, INC. 2004-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186160-A1 Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors MAP3K15, MAP3K20, MAP3K19 AHR 810/4885PDK2 381/4885NPC1 4440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.